Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ahmad Awada

Showing results (221-230 of 311) with videos related to

Pageof 32
Sort By:
BMC Cancer|June 3, 2014
Correlating tumor metabolic progression index measured by serial FDG PET-CT, apparent diffusion coefficient measured by magnetic resonance imaging (MRI) and blood genomics to patient's outcome in advanced colorectal cancer: the CORIOLAN studyAmelie Deleporte, Marianne Paesmans, Camilo Garcia, et al.
Clinical Breast Cancer|January 4, 2022
Beta-2 Adrenergic Receptor Gene Expression in HER2-Positive Early-Stage Breast Cancer Patients: A Post-hoc Analysis of the NCCTG-N9831 (Alliance) TrialRafael Caparica, Yaohua Ma, Claudia De Angelis, et al.
Investigational New Drugs|August 4, 2010
A phase 1 study of BMS-275183, a novel oral analogue of paclitaxel given on a daily schedule to patients with advanced malignanciesElisabeth I Heath, Patricia Lorusso, Suresh S Ramalingam, et al.
Journal of Clinical Pharmacology|January 7, 2011
Safety and pharmacokinetics of sorafenib combined with capecitabine in patients with advanced solid tumors: results of a phase 1 trialAhmad Awada, Thierry Gil, Nicolas Whenham, et al.
European Journal of Cancer (Oxford, England : 1990)|April 24, 2016
Results of the Belgian expanded access program of eribulin in the treatment of metastatic breast cancer closely mirror those of the pivotal phase III trialPhilippe Aftimos, Laura Polastro, Lieveke Ameye, et al.
Clinical Breast Cancer|July 22, 2025
Characteristics, Treatment Patterns and Clinical Outcomes of Women with Maghreb Origin and Diagnosis of Breast Cancer: A Single-Center, Retrospective Cohort StudyChiara Dauccia, Diogo Martins-Branco, Michel Moreau, et al.
Journal of Chemotherapy (Florence, Italy)|August 3, 2013
Comparison of a gene expression profiling strategy to standard clinical work-up for determination of tumour origin in cancer of unknown primary (CUP)Felipe Ades, Evandro de Azambuja, Gedske Daugaard, et al.
Journal for Immunotherapy of Cancer|July 10, 2020
Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohortByoung Chul Cho, Amaury Daste, Alain Ravaud, et al.
NPJ Breast Cancer|January 25, 2019
MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancerStephen Johnston, Miguel Martin, Angelo Di Leo, et al.
European Journal of Cancer (Oxford, England : 1990)|May 14, 2022
First-in-man, first-in-class phase I study with the monopolar spindle 1 kinase inhibitor S81694 administered intravenously in adult patients with advanced, metastatic solid tumoursPatrick Schöffski, Ahmad Awada, Anne-Marie de la Bigne, et al.
Pageof 32

Showing results (221-230 of 311) with videos related to

Sort By:
Pageof 32
BMC Cancer|June 3, 2014
Correlating tumor metabolic progression index measured by serial FDG PET-CT, apparent diffusion coefficient measured by magnetic resonance imaging (MRI) and blood genomics to patient's outcome in advanced colorectal cancer: the CORIOLAN studyAmelie Deleporte, Marianne Paesmans, Camilo Garcia, et al.
Clinical Breast Cancer|January 4, 2022
Beta-2 Adrenergic Receptor Gene Expression in HER2-Positive Early-Stage Breast Cancer Patients: A Post-hoc Analysis of the NCCTG-N9831 (Alliance) TrialRafael Caparica, Yaohua Ma, Claudia De Angelis, et al.
Investigational New Drugs|August 4, 2010
A phase 1 study of BMS-275183, a novel oral analogue of paclitaxel given on a daily schedule to patients with advanced malignanciesElisabeth I Heath, Patricia Lorusso, Suresh S Ramalingam, et al.
Journal of Clinical Pharmacology|January 7, 2011
Safety and pharmacokinetics of sorafenib combined with capecitabine in patients with advanced solid tumors: results of a phase 1 trialAhmad Awada, Thierry Gil, Nicolas Whenham, et al.
European Journal of Cancer (Oxford, England : 1990)|April 24, 2016
Results of the Belgian expanded access program of eribulin in the treatment of metastatic breast cancer closely mirror those of the pivotal phase III trialPhilippe Aftimos, Laura Polastro, Lieveke Ameye, et al.
Clinical Breast Cancer|July 22, 2025
Characteristics, Treatment Patterns and Clinical Outcomes of Women with Maghreb Origin and Diagnosis of Breast Cancer: A Single-Center, Retrospective Cohort StudyChiara Dauccia, Diogo Martins-Branco, Michel Moreau, et al.
Journal of Chemotherapy (Florence, Italy)|August 3, 2013
Comparison of a gene expression profiling strategy to standard clinical work-up for determination of tumour origin in cancer of unknown primary (CUP)Felipe Ades, Evandro de Azambuja, Gedske Daugaard, et al.
Journal for Immunotherapy of Cancer|July 10, 2020
Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohortByoung Chul Cho, Amaury Daste, Alain Ravaud, et al.
NPJ Breast Cancer|January 25, 2019
MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancerStephen Johnston, Miguel Martin, Angelo Di Leo, et al.
European Journal of Cancer (Oxford, England : 1990)|May 14, 2022
First-in-man, first-in-class phase I study with the monopolar spindle 1 kinase inhibitor S81694 administered intravenously in adult patients with advanced, metastatic solid tumoursPatrick Schöffski, Ahmad Awada, Anne-Marie de la Bigne, et al.
Pageof 32